The nutritional management of a patient with acute myeloid leukaemia
Keywords: nutritional, management, acute myeloid leukaemia, promyelocytic
AbstractAcute promyelocytic leukaemia (APL) is a subtype of acute myeloid leukaemia (AML), categorised as AML subtype M3, and is characterised by translocation of the genes between the long (q) legs of chromosomes 15 and 17 [described as t 15;17)(q24;q21)]. There are two different classification systems for AML, namely the World Health Organization (WHO) and the French-American-British (FAB) classifications. The FAB classification divides AML into eight subtypes based on morphology and the cytochemical staining of blasts.1 The WHO classification is more complicated, since it requires evaluation of the blast cells by molecular analysis and flow cytometry.1 Classification of the different types of AML is valuable to doctors when deciding on which chemotherapy regimen to use after remission has been achieved since each type may react differently to treatment owing to its different genetic make-up.2 APL usually has a good prognosis.3,4
How to Cite
Tydeman-Edwards, R. (2015). The nutritional management of a patient with acute myeloid leukaemia. South African Journal of Clinical Nutrition, 28(4), 187-194. Retrieved from http://sajcn.co.za/index.php/SAJCN/article/view/1063
SASPEN Case Study
Material submitted for publication in the South African Journal of Clinical Nutrition (SAJCN) is accepted provided it has not been published elsewhere. Copyright forms will be sent with acknowledgement of receipt and the SAJCN reserves copyright of the material published.
The SAJCN does not hold itself responsible for statements made by the authors.